Compare · ARVN vs NVS
ARVN vs NVS
Side-by-side comparison of Arvinas Inc. (ARVN) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARVN and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.70B, about 642.0x ARVN ($457.5M).
- Over the past year, ARVN is down 7.6% and NVS is up 30.5% - NVS leads by 38.1 points.
- ARVN has been more active in the news (4 items in the past 4 weeks vs 1 for NVS).
- Both have 25 recent analyst ratings on file.
- Company
- Arvinas Inc.
- Novartis AG
- Price
- $7.08+1.29%
- $153.94+3.94%
- Market cap
- $457.5M
- $293.70B
- 1M return
- -26.04%
- +3.87%
- 1Y return
- -7.63%
- +30.46%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 25
Arvinas Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest ARVN
- Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease
- Arvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Arvinas to Present at Jefferies Global Healthcare Conference
- President and CEO Teel Randy sold $19,962 worth of shares (2,209 units at $9.04), decreasing direct ownership by 0.77% to 285,009 units (SEC Form 4) (tax liability)
- Chief Financial Officer Saik Andrew sold $110,693 worth of shares (11,139 units at $9.94), decreasing direct ownership by 5% to 193,128 units (SEC Form 4) to satisfy withholding obligation
- Chief Scientific Officer Cacace Angela M sold $95,965 worth of shares (9,657 units at $9.94), decreasing direct ownership by 5% to 182,966 units (SEC Form 4) to cover withholding tax
- VP, Chief Accounting Officer Loomis David K sold $19,070 worth of shares (1,919 units at $9.94), decreasing direct ownership by 5% to 40,193 units (SEC Form 4) to satisfy withholding tax
- Chief Medical Officer Berkowitz Noah sold $110,385 worth of shares (11,108 units at $9.94), decreasing direct ownership by 5% to 191,395 units (SEC Form 4) (withholding obligation)
- President and CEO Teel Randy sold $95,965 worth of shares (9,657 units at $9.94), decreasing direct ownership by 3% to 287,218 units (SEC Form 4) (withholding tax)
- Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG